首页 > 最新文献

European Clinical Respiratory Journal最新文献

英文 中文
Endoscopic ultrasound-guided fine-needle aspiration using the bronchial ultrasound scope (EUS-B-FNA) for diagnosing pancreatic metastasis in a lung cancer patient case report. 使用支气管超声内窥镜进行内窥镜超声引导细针穿刺术(EUS-B-FNA)诊断肺癌患者胰腺转移的病例报告。
IF 1.9 Q3 Medicine Pub Date : 2023-12-25 eCollection Date: 2024-01-01 DOI: 10.1080/20018525.2023.2294545
Abdul Khaliq Ahmad, Arman Arshad, Christian B Laursen, Vasiliki Panou

Endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNA) of the pancreas is performed routinely in many endoscopic centers as part of the diagnostic set-up for suspected pancreatic cancer. The use of transesophageal bronchoscopic ultrasound-guided fine needle aspiration (EUS-B-FNA) by pulmonologists has expanded significantly, since it enables effective diagnosis of lesions in the mediastinum and upper abdomen. The following case demonstrates the safety and feasibility of EUS-B-FNA in a patient with non-small cell lung cancer (NSCLC) cancer and a pancreatic mass of unknown origin. A patient who was previously diagnosed with NSCLC was referred to the Department of Respiratory Medicine, Odense University Hospital due to suspected recurrence of NSCLC. The patient underwent endobronchial ultrasound guided (EBUS)-FNA from several suspected mediastinal lymph nodes and combined EUS-B-FNA from a pancreatic mass during the same procedure. Pathology results from the pancreatic mass and from the mediastinal lymph nodes showed squamous-cell carcinoma, metastasis from the previous NSCLC. We here by demonstrated that EUS-B-FNA is a feasible and safe technique to obtain tissue samples from pancreatic lesions in patients under investigation for lung cancer.

胰腺内镜超声引导细针穿刺活检(EUS-FNA)是许多内镜中心的常规检查项目,也是疑似胰腺癌诊断程序的一部分。由于经食道支气管镜超声引导细针穿刺活检术(EUS-B-FNA)能有效诊断纵隔和上腹部的病变,因此肺科医生对它的使用范围也大大扩展。下面的病例展示了 EUS-B-FNA 在一名患有非小细胞肺癌(NSCLC)和不明原因胰腺肿块的患者身上的安全性和可行性。一名曾被诊断为 NSCLC 的患者因怀疑 NSCLC 复发而被转诊至欧登塞大学医院呼吸内科。患者在同一手术中接受了支气管内超声引导(EBUS)-FNA检查,检查了多个疑似纵隔淋巴结,并对胰腺肿块进行了EUS-B-FNA联合检查。胰腺肿块和纵隔淋巴结的病理结果显示为鳞状细胞癌,由之前的 NSCLC 转移而来。我们在此证明,EUS-B-FNA 是一种可行且安全的技术,可用于从肺癌受检患者的胰腺病变中获取组织样本。
{"title":"Endoscopic ultrasound-guided fine-needle aspiration using the bronchial ultrasound scope (EUS-B-FNA) for diagnosing pancreatic metastasis in a lung cancer patient case report.","authors":"Abdul Khaliq Ahmad, Arman Arshad, Christian B Laursen, Vasiliki Panou","doi":"10.1080/20018525.2023.2294545","DOIUrl":"10.1080/20018525.2023.2294545","url":null,"abstract":"<p><p>Endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNA) of the pancreas is performed routinely in many endoscopic centers as part of the diagnostic set-up for suspected pancreatic cancer. The use of transesophageal bronchoscopic ultrasound-guided fine needle aspiration (EUS-B-FNA) by pulmonologists has expanded significantly, since it enables effective diagnosis of lesions in the mediastinum and upper abdomen. The following case demonstrates the safety and feasibility of EUS-B-FNA in a patient with non-small cell lung cancer (NSCLC) cancer and a pancreatic mass of unknown origin. A patient who was previously diagnosed with NSCLC was referred to the Department of Respiratory Medicine, Odense University Hospital due to suspected recurrence of NSCLC. The patient underwent endobronchial ultrasound guided (EBUS)-FNA from several suspected mediastinal lymph nodes and combined EUS-B-FNA from a pancreatic mass during the same procedure. Pathology results from the pancreatic mass and from the mediastinal lymph nodes showed squamous-cell carcinoma, metastasis from the previous NSCLC. We here by demonstrated that EUS-B-FNA is a feasible and safe technique to obtain tissue samples from pancreatic lesions in patients under investigation for lung cancer.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A five-gene qPCR signature can classify type 2 asthma comparably to microscopy of induced sputum from severe asthma patients 五基因 qPCR 特征可对 2 型哮喘进行分类,与重症哮喘患者诱导痰的显微镜检查结果相当
IF 1.9 Q3 Medicine Pub Date : 2023-12-21 DOI: 10.1080/20018525.2023.2293318
B. Toennesen, J. M. Schmid, B. S. Sørensen, M. Fricker, H. J. Hoffmann
{"title":"A five-gene qPCR signature can classify type 2 asthma comparably to microscopy of induced sputum from severe asthma patients","authors":"B. Toennesen, J. M. Schmid, B. S. Sørensen, M. Fricker, H. J. Hoffmann","doi":"10.1080/20018525.2023.2293318","DOIUrl":"https://doi.org/10.1080/20018525.2023.2293318","url":null,"abstract":"","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138951701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of laryngotracheal lesions in tracheostomized COVID-19 patients. A comparison with a matched historical control group of non-COVID-19 patients 气管造口术 COVID-19 患者的喉气管病变发生率。与非 COVID-19 患者的匹配历史对照组进行比较
IF 1.9 Q3 Medicine Pub Date : 2023-12-02 DOI: 10.1080/20018525.2023.2283265
Juan Manuel Carballo, Antonela Vicente, Ladislao Diaz Ballve, María Paula Pedace, P. Tocalini, Eliana Pérez Calvo, Karen Torres, Fernando Planells, Dario Villalba
{"title":"Prevalence of laryngotracheal lesions in tracheostomized COVID-19 patients. A comparison with a matched historical control group of non-COVID-19 patients","authors":"Juan Manuel Carballo, Antonela Vicente, Ladislao Diaz Ballve, María Paula Pedace, P. Tocalini, Eliana Pérez Calvo, Karen Torres, Fernando Planells, Dario Villalba","doi":"10.1080/20018525.2023.2283265","DOIUrl":"https://doi.org/10.1080/20018525.2023.2283265","url":null,"abstract":"","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138606558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agreement between reported questionnaire data and medical records on diagnosis and COVID-19 symptoms at onset 所报告的问卷数据与医疗记录中的诊断和 COVID-19 发病症状之间的一致性
IF 1.9 Q3 Medicine Pub Date : 2023-11-18 DOI: 10.1080/20018525.2023.2282251
M. Kisiel, Claes Kock, Josef Sultan, Helena Janols, Christer Janson, Ronnie Pingel
ABSTRACT The aim of this study was to assess whether there was agreement between self-reported data in a survey and medical records regarding diagnoses and symptoms at COVID-19 onset. The impact of sociodemographic factors on agreement between the two data sources was also assessed. Cross-sectional data were extracted from a Swedish longitudinal cohort study. In total, 401 non-hospitalized patients with a polymerase chain reaction-confirmed COVID-19 infection responded to a survey and agreed to a review of their electronic medical records. Agreement, estimated using the kappa statistic, sensitivity, and specificity were calculated for nine diagnoses and eleven symptoms. Differences between subgroups based on sociodemographic factors were assessed. The agreement between the self-reported data and medical records was at a substantial to moderate level for diagnoses such as diabetes mellitus (kappa 0.65, sensitivity 86%) and hypertension (kappa 0.59, sensitivity 56%) and at a fair level for more difficult-to-define conditions such as ongoing immunosuppressive treatment (kappa 0.27, sensitivity 25%). The agreement between the two data sources on symptoms was between fair and poor (kappa 0.36 for fever; kappa 0.05 for fatigue). Agreement for some diagnoses and symptoms varied across some sociodemographic subgroups, e.g. agreement in diabetes mellitus was significantly better in males (kappa 1.0) than females (kappa 0.52, homogeneity tests p = 0.02). In general, kappa values were lower for symptoms than diagnoses. The agreement between the two sources varied with diagnoses and symptoms and was also influenced by sociodemographic factors. This study illustrates that it is important to consider type of data used in the epidemiological studies as different information sources differ with quality and accuracy.
摘要 本研究旨在评估一项调查中的自我报告数据与 COVID-19 发病时的诊断和症状方面的医疗记录是否一致。此外,还评估了社会人口因素对两种数据来源之间一致性的影响。横断面数据来自瑞典的一项纵向队列研究。共有 401 名经聚合酶链反应确诊感染 COVID-19 的非住院患者接受了调查,并同意查阅其电子病历。针对九种诊断和十一种症状计算了卡帕统计估计的一致性、敏感性和特异性。评估了基于社会人口学因素的亚组之间的差异。在糖尿病(kappa 0.65,灵敏度 86%)和高血压(kappa 0.59,灵敏度 56%)等诊断方面,自我报告数据与医疗记录之间的一致性达到了相当高到中等的水平,而在较难界定的病症方面,如正在进行的免疫抑制治疗(kappa 0.27,灵敏度 25%),两者之间的一致性达到了一般水平。两个数据源在症状方面的一致性介于一般和较差之间(发热的 kappa 值为 0.36;疲劳的 kappa 值为 0.05)。在一些社会人口亚群中,某些诊断和症状的一致性存在差异,例如,男性在糖尿病方面的一致性(kappa 1.0)明显优于女性(kappa 0.52,同质性检验 p = 0.02)。一般来说,症状的 kappa 值低于诊断的 kappa 值。两种来源的一致性因诊断和症状而异,也受社会人口因素的影响。这项研究表明,考虑流行病学研究中使用的数据类型非常重要,因为不同的信息来源在质量和准确性方面存在差异。
{"title":"Agreement between reported questionnaire data and medical records on diagnosis and COVID-19 symptoms at onset","authors":"M. Kisiel, Claes Kock, Josef Sultan, Helena Janols, Christer Janson, Ronnie Pingel","doi":"10.1080/20018525.2023.2282251","DOIUrl":"https://doi.org/10.1080/20018525.2023.2282251","url":null,"abstract":"ABSTRACT The aim of this study was to assess whether there was agreement between self-reported data in a survey and medical records regarding diagnoses and symptoms at COVID-19 onset. The impact of sociodemographic factors on agreement between the two data sources was also assessed. Cross-sectional data were extracted from a Swedish longitudinal cohort study. In total, 401 non-hospitalized patients with a polymerase chain reaction-confirmed COVID-19 infection responded to a survey and agreed to a review of their electronic medical records. Agreement, estimated using the kappa statistic, sensitivity, and specificity were calculated for nine diagnoses and eleven symptoms. Differences between subgroups based on sociodemographic factors were assessed. The agreement between the self-reported data and medical records was at a substantial to moderate level for diagnoses such as diabetes mellitus (kappa 0.65, sensitivity 86%) and hypertension (kappa 0.59, sensitivity 56%) and at a fair level for more difficult-to-define conditions such as ongoing immunosuppressive treatment (kappa 0.27, sensitivity 25%). The agreement between the two data sources on symptoms was between fair and poor (kappa 0.36 for fever; kappa 0.05 for fatigue). Agreement for some diagnoses and symptoms varied across some sociodemographic subgroups, e.g. agreement in diabetes mellitus was significantly better in males (kappa 1.0) than females (kappa 0.52, homogeneity tests p = 0.02). In general, kappa values were lower for symptoms than diagnoses. The agreement between the two sources varied with diagnoses and symptoms and was also influenced by sociodemographic factors. This study illustrates that it is important to consider type of data used in the epidemiological studies as different information sources differ with quality and accuracy.","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139262210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introduction of a systematic examination framework for chronic cough: a before-after cohort study in a clinical setting. 慢性咳嗽系统检查框架的引入:临床环境中的前后队列研究。
IF 1.9 Q3 Medicine Pub Date : 2023-10-31 eCollection Date: 2023-01-01 DOI: 10.1080/20018525.2023.2273026
Allan Klitgaard, Anders Løkke, Jannie Frølund, Steffen Kristensen, Ole Hilberg

Cough is a condition that can be caused by several different mechanisms. There are numerous guidelines for diagnosing the cause of cough, yet the effect of a well-constructed examination framework has not been investigated. At the Department of Internal Medicine, Lillebaelt Hospital, Vejle, a systematic examination framework for diagnosing cough was introduced. Two hundred consecutive patients referred to the pulmonary outpatient clinic with cough were included. The first 100 patients (Group 1) were included before implementation of the examination framework and diagnosed as usual. The next 100 patients (Group 2) were examined using the systematic framework. The primary endpoint was the number of appointments required to establish a diagnosis. A multivariable Poisson regression was performed, adjusting for age, sex, body mass index, pulmonary function (FEV1/FVC), duration of cough, and smoking status. A diagnosis was established within 1-2 visits in 47% in Group 1 compared to 83% in Group 2. When adjusting for confounders, fewer appointments was required to establish a diagnosis in Group 2 (Incidence rate ratio = 0.713 (95% confidence interval: 0.592-0.859), P = 0.000). Using a systematic examination framework for diagnosing cough may reduce the number of appointments required to establish a diagnosis, seemingly without compromising the diagnostic outcome.

咳嗽是一种由多种不同机制引起的疾病。有许多诊断咳嗽原因的指南,但构建良好的检查框架的效果尚未得到调查。在Vejle Lillebelt医院内科,介绍了一种诊断咳嗽的系统检查框架。连续200名因咳嗽而转诊到肺部门诊的患者也包括在内。前100名患者(第1组)在实施检查框架之前被纳入,并像往常一样进行诊断。接下来的100名患者(第2组)使用系统框架进行检查。主要终点是确定诊断所需的预约次数。进行多变量泊松回归,调整年龄、性别、体重指数、肺功能(FEV1/FVC)、咳嗽持续时间和吸烟状况。第一组47%的患者在1-2次就诊中确诊,而第二组为83%。当对混杂因素进行调整时,第2组需要更少的预约来确定诊断(发病率比率 = 0.713(95%置信区间:0.592-0.859),P = 0.000)。使用系统的检查框架来诊断咳嗽可以减少确定诊断所需的预约次数,似乎不会影响诊断结果。
{"title":"Introduction of a systematic examination framework for chronic cough: a before-after cohort study in a clinical setting.","authors":"Allan Klitgaard,&nbsp;Anders Løkke,&nbsp;Jannie Frølund,&nbsp;Steffen Kristensen,&nbsp;Ole Hilberg","doi":"10.1080/20018525.2023.2273026","DOIUrl":"https://doi.org/10.1080/20018525.2023.2273026","url":null,"abstract":"<p><p>Cough is a condition that can be caused by several different mechanisms. There are numerous guidelines for diagnosing the cause of cough, yet the effect of a well-constructed examination framework has not been investigated. At the Department of Internal Medicine, Lillebaelt Hospital, Vejle, a systematic examination framework for diagnosing cough was introduced. Two hundred consecutive patients referred to the pulmonary outpatient clinic with cough were included. The first 100 patients (Group 1) were included before implementation of the examination framework and diagnosed as usual. The next 100 patients (Group 2) were examined using the systematic framework. The primary endpoint was the number of appointments required to establish a diagnosis. A multivariable Poisson regression was performed, adjusting for age, sex, body mass index, pulmonary function (FEV1/FVC), duration of cough, and smoking status. A diagnosis was established within 1-2 visits in 47% in Group 1 compared to 83% in Group 2. When adjusting for confounders, fewer appointments was required to establish a diagnosis in Group 2 (Incidence rate ratio = 0.713 (95% confidence interval: 0.592-0.859), <i>P</i> = 0.000). Using a systematic examination framework for diagnosing cough may reduce the number of appointments required to establish a diagnosis, seemingly without compromising the diagnostic outcome.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age at asthma diagnosis and onset of symptoms among adults with allergic and non-allergic asthma. 成人过敏性和非过敏性哮喘的哮喘诊断年龄和症状发作。
IF 1.9 Q3 Medicine Pub Date : 2023-10-18 eCollection Date: 2023-01-01 DOI: 10.1080/20018525.2023.2269653
Johanna Pakkasela, Petri Salmela, Pekka Juntunen, Jussi Karjalainen, Lauri Lehtimäki

Background: Childhood-onset allergic asthma is the best-known phenotype of asthma. Adult-onset asthma, also an important entity, is instead often shown to be more non-allergic. There is still a lack of studies concerning the association of allergies and age at asthma onset from childhood to late adulthood. The aim of the study was to assess the age at onset of asthma symptoms and age at asthma diagnosis among adults with allergic and non-allergic asthma.

Methods: Questionnaires were sent to 2000 randomly selected Finnish adults aged 18-80 years who were dispensed medication for obstructive airway diseases during the previous year. The corrected sample size was 1978 subjects after exclusion of non-analysable data. The response rate was 40.6%. Self-reported doctor-diagnosed asthma was considered allergic if a concomitant self-reported doctor-diagnosed pollen and/or animal allergy was reported with asthma symptoms upon allergen exposure.

Results: Of the 496 participants with asthma, 42.7% were considered to have allergic asthma. The median ages at asthma diagnosis and onset of asthma symptoms were 31 (IQR 17-46) and 20 (9.25-40) years in participants with allergic asthma and 49 (37.75-58) and 40.5 (30-50) years in participants with non-allergic asthma (p < 0.001), respectively. Of the participants with asthma diagnosed at ≥30 years of age, 18% of allergic and 7% of non-allergic participants reported having had asthma symptoms under 20 years of age.

Conclusions: Both the onset of symptoms and diagnosis occurred at a younger age among adults with allergic asthma than among those with non-allergic asthma. Only a minority of adults with non-allergic asthma had already had symptoms in younghood.

背景:儿童期发作的过敏性哮喘是最著名的哮喘表型。成人哮喘也是一种重要的疾病,通常表现为非过敏性。从儿童期到成年晚期,过敏与哮喘发病年龄之间的关系仍然缺乏研究。本研究的目的是评估成人过敏性和非过敏性哮喘患者出现哮喘症状的年龄和诊断哮喘的年龄。方法:随机抽取2000名18-80岁的芬兰成年人进行问卷调查 在过去的一年中,为患有阻塞性呼吸道疾病的患者分配了药物。排除不可分析的数据后,校正的样本量为1978名受试者。有效率为40.6%。如果同时自我报告的医生诊断花粉和/或动物过敏,并报告暴露于过敏原后出现哮喘症状,则自我报告的医师诊断哮喘被视为过敏。结果:496名哮喘患者中,42.7%被认为患有过敏性哮喘。过敏性哮喘患者诊断哮喘和出现哮喘症状的中位年龄分别为31岁(IQR 17-46)和20岁(9.25-40),非过敏性哮喘参与者分别为49岁(37.75-58)和40.5岁(30-50)(p 结论:与非过敏性哮喘患者相比,成人过敏性哮喘的症状和诊断发生在更年轻的年龄。只有少数患有非过敏性哮喘的成年人在幼年时就已经出现了症状。
{"title":"Age at asthma diagnosis and onset of symptoms among adults with allergic and non-allergic asthma.","authors":"Johanna Pakkasela,&nbsp;Petri Salmela,&nbsp;Pekka Juntunen,&nbsp;Jussi Karjalainen,&nbsp;Lauri Lehtimäki","doi":"10.1080/20018525.2023.2269653","DOIUrl":"10.1080/20018525.2023.2269653","url":null,"abstract":"<p><strong>Background: </strong>Childhood-onset allergic asthma is the best-known phenotype of asthma. Adult-onset asthma, also an important entity, is instead often shown to be more non-allergic. There is still a lack of studies concerning the association of allergies and age at asthma onset from childhood to late adulthood. The aim of the study was to assess the age at onset of asthma symptoms and age at asthma diagnosis among adults with allergic and non-allergic asthma.</p><p><strong>Methods: </strong>Questionnaires were sent to 2000 randomly selected Finnish adults aged 18-80 years who were dispensed medication for obstructive airway diseases during the previous year. The corrected sample size was 1978 subjects after exclusion of non-analysable data. The response rate was 40.6%. Self-reported doctor-diagnosed asthma was considered allergic if a concomitant self-reported doctor-diagnosed pollen and/or animal allergy was reported with asthma symptoms upon allergen exposure.</p><p><strong>Results: </strong>Of the 496 participants with asthma, 42.7% were considered to have allergic asthma. The median ages at asthma diagnosis and onset of asthma symptoms were 31 (IQR 17-46) and 20 (9.25-40) years in participants with allergic asthma and 49 (37.75-58) and 40.5 (30-50) years in participants with non-allergic asthma (<i>p</i> < 0.001), respectively. Of the participants with asthma diagnosed at ≥30 years of age, 18% of allergic and 7% of non-allergic participants reported having had asthma symptoms under 20 years of age.</p><p><strong>Conclusions: </strong>Both the onset of symptoms and diagnosis occurred at a younger age among adults with allergic asthma than among those with non-allergic asthma. Only a minority of adults with non-allergic asthma had already had symptoms in younghood.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/90/ZECR_10_2269653.PMC10586087.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thoracic ultrasonographic and clinical findings at 12-month follow-up of patients admitted with COVID-19. 新冠肺炎患者12个月随访时的胸部超声和临床表现。
IF 1.9 Q3 Medicine Pub Date : 2023-09-24 eCollection Date: 2023-01-01 DOI: 10.1080/20018525.2023.2257992
Casper Falster, Amanda Juul, Niels Jacobsen, Inge Raadal Skov, Line Dahlerup Rasmussen, Lone Wulff Madsen, Isik Somuncu Johansen, Stefan Markus Walbom Harders Harders, Jesper Rømhild Davidsen, Christian B Laursen

Introduction: Thoracic ultrasound (TUS) has proven useful in the diagnosis, risk stratification and monitoring of disease progression in patients with coronavirus disease 2019 (COVID-19). However, utility in follow-up is poorly described. To elucidate this area, we performed TUS as part of a 12-month clinical follow-up in patients previously admitted with COVID-19 and correlated findings with clinical assessment and pulmonary function tests.

Methods: Adult patients discharged from our hospital following admission with COVID-19 during March to May 2020 were invited to a 12-month follow-up. Enrolled patients were interviewed regarding persisting or newly developed symptoms in addition to TUS, spirometry and a 6-min walk test. Patients were referred to high-resolution computed tomography (HRCT) of the lungs if suspicion of pulmonary fibrosis was raised.

Results: Forty patients were enrolled in the study of whom had 13 developed acute respiratory distress syndrome (ARDS) during admission. Patients with ARDS were more prone to experience neurological symptoms at follow-up (p = 0.03) and showed more B-lines on TUS (p = 0.008) but did not otherwise differ significantly in terms of pulmonary function tests. Four patients had pathological findings on TUS where subsequent diagnostics revealed that two had interstitial lung abnormalities and two had heart failure. These four patients presented with a significantly lower diffusing capacity of lung for carbon monoxide (p=0.03) and 6-min walking distance (p=0.006) compared to the remaining 36 patients without ultrasound pathology. No significant difference was observed in spirometry values of % of predicted FEV1 (p=0.49) or FVC (p=0.07). No persisting cardiovascular pathology was observed in patients without ultrasonographic pathology.

Conclusion: At 12-month after admission with COVID-19, a follow-up combining TUS, clinical assessment, and pulmonary function tests may improve the selection of patients requiring further diagnostic investigations such as HRCT or echocardiography.

简介:胸部超声(TUS)已被证明可用于2019冠状病毒病(新冠肺炎)患者的诊断、风险分层和疾病进展监测。然而,对后续行动的效用描述不多。为了阐明这一领域,我们对先前入住新冠肺炎的患者进行了为期12个月的临床随访,并将研究结果与临床评估和肺功能测试相关联。方法:邀请2020年3月至5月新冠肺炎住院后出院的成年患者进行为期12个月的随访。除了TUS、肺活量测定和6分钟步行测试外,还就持续或新出现的症状对入选患者进行了访谈。如果怀疑有肺纤维化,则将患者转诊至肺部的高分辨率计算机断层扫描(HRCT)。结果:40名患者被纳入研究,其中13人在入院期间出现急性呼吸窘迫综合征(ARDS)。ARDS患者在随访中更容易出现神经系统症状(p = 0.03),并且在TUS上显示出更多的B线(p = 0.008),但在肺功能测试方面没有显著差异。四名患者在TUS上有病理学发现,随后的诊断显示两名患者有间质性肺异常,两名患者患有心力衰竭。与其余36名无超声病理的患者相比,这4名患者的肺部一氧化碳扩散能力(p=0.03)和6分钟步行距离(p=0.006)显著降低。预测的FEV1(p=0.49)或FVC(p=0.07)的肺活量测定值%没有观察到显著差异。在没有超声病理的患者中没有观察到持续的心血管病理。结论:在新冠肺炎入院后12个月,结合TUS、临床评估和肺功能测试的随访可能会改善需要进一步诊断研究(如HRCT或超声心动图)的患者的选择。
{"title":"Thoracic ultrasonographic and clinical findings at 12-month follow-up of patients admitted with COVID-19.","authors":"Casper Falster,&nbsp;Amanda Juul,&nbsp;Niels Jacobsen,&nbsp;Inge Raadal Skov,&nbsp;Line Dahlerup Rasmussen,&nbsp;Lone Wulff Madsen,&nbsp;Isik Somuncu Johansen,&nbsp;Stefan Markus Walbom Harders Harders,&nbsp;Jesper Rømhild Davidsen,&nbsp;Christian B Laursen","doi":"10.1080/20018525.2023.2257992","DOIUrl":"https://doi.org/10.1080/20018525.2023.2257992","url":null,"abstract":"<p><strong>Introduction: </strong>Thoracic ultrasound (TUS) has proven useful in the diagnosis, risk stratification and monitoring of disease progression in patients with coronavirus disease 2019 (COVID-19). However, utility in follow-up is poorly described. To elucidate this area, we performed TUS as part of a 12-month clinical follow-up in patients previously admitted with COVID-19 and correlated findings with clinical assessment and pulmonary function tests.</p><p><strong>Methods: </strong>Adult patients discharged from our hospital following admission with COVID-19 during March to May 2020 were invited to a 12-month follow-up. Enrolled patients were interviewed regarding persisting or newly developed symptoms in addition to TUS, spirometry and a 6-min walk test. Patients were referred to high-resolution computed tomography (HRCT) of the lungs if suspicion of pulmonary fibrosis was raised.</p><p><strong>Results: </strong>Forty patients were enrolled in the study of whom had 13 developed acute respiratory distress syndrome (ARDS) during admission. Patients with ARDS were more prone to experience neurological symptoms at follow-up (<i>p</i> = 0.03) and showed more B-lines on TUS (<i>p</i> = 0.008) but did not otherwise differ significantly in terms of pulmonary function tests. Four patients had pathological findings on TUS where subsequent diagnostics revealed that two had interstitial lung abnormalities and two had heart failure. These four patients presented with a significantly lower diffusing capacity of lung for carbon monoxide (<i>p</i>=0.03) and 6-min walking distance (<i>p</i>=0.006) compared to the remaining 36 patients without ultrasound pathology. No significant difference was observed in spirometry values of % of predicted FEV1 (<i>p</i>=0.49) or FVC (<i>p</i>=0.07). No persisting cardiovascular pathology was observed in patients without ultrasonographic pathology.</p><p><strong>Conclusion: </strong>At 12-month after admission with COVID-19, a follow-up combining TUS, clinical assessment, and pulmonary function tests may improve the selection of patients requiring further diagnostic investigations such as HRCT or echocardiography.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/62/ZECR_10_2257992.PMC10519251.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41117091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial. COPD患者急性高碳酸血症呼吸衰竭加重后的长期无创通气:一项随机对照试验。
IF 1.9 Q3 Medicine Pub Date : 2023-09-18 eCollection Date: 2023-01-01 DOI: 10.1080/20018525.2023.2257993
Caroline Hedsund, Kasper Linde Ankjærgaard, Tine Peick Sonne, Philip Tønnesen, Ejvind Frausing Hansen, Helle Frost Andreassen, Ronan M G Berg, Jens-Ulrik Stæhr Jensen, Jon Torgny Wilcke

Introduction: It remains unclear whether long-term non-invasive ventilation (LT-NIV) for patients with chronic obstructive pulmonary disease (COPD) improves survival and reduces admissions as results from randomized trials are inconsistent. We aim to determine whether LT-NIV initiated after an admission with acute hypercapnic respiratory failure (AHRF) can affect survival and admission rate in COPD patients.

Methods: A randomized controlled open-label trial, allocating patients with COPD to LT-NIV or standard of care immediately after an admission with AHRF treated with acute NIV. LT-NIV was aimed to normalize PaCO2 using high-pressure NIV.

Results: The study was discontinued before full sample size due to slow recruitment. 28 patients were randomized to LT-NIV and 27 patients to standard of care. 42% of patients had a history of ≥ 2 admissions with AHRF. Median IPAP was 24 cmH2O (IQR 20-28). The primary outcome, time to readmission with AHRF or death within 12 months, did not reach significance, hazard ratio 0.53 (95% CI 0.25-1.12) p = 0.097. In a competing risk analysis, adjusted for history of AHRF, the odds ratio for AHRF within 12 months was 0.30 (95% CI 0.11-0.87) p = 0.024. The LT-NIV group had less exacerbations (median 1 (0-1) vs 2 (1-4) p = 0.021) and readmissions with AHRF (median 0 (0-1) vs 1 (0-1) p = 0.016).

Conclusion: The risk of the primary outcome, time to readmission with AHRF or death within 12 months was numerically smaller in the LT-NIV group, however, did not reach significance. Nevertheless, several secondary outcome analyses like risk of AHRF, number of episodes of AHRF and exacerbations were all significantly reduced in favour of high-pressure LT-NIV, especially in patients with frequent AHRF.

引言:由于随机试验的结果不一致,目前尚不清楚慢性阻塞性肺病(COPD)患者的长期无创通气(LT-NIV)是否能提高生存率并减少入院人数。我们的目的是确定急性高碳酸血症呼吸衰竭(AHRF)患者入院后开始的LT-NIV是否会影响COPD患者的生存率和入院率。方法:一项随机对照开放标签试验,将COPD患者分配到LT-NIV或标准护理,在接受AHRF治疗后立即接受急性NIV治疗。LT-NIV旨在使用高压NIV使PaCO2标准化。结果:由于招募缓慢,该研究在完全样本量之前停止。28名患者随机接受LT-NIV治疗,27名患者接受标准护理。42%的患者有 ≥ 2例AHRF患者入院。IPAP中位数为24 cmH2O(IQR 20-28)。主要结果,AHRF再次入院时间或12年内死亡 月,未达到显著性,危险比0.53(95%CI 0.25-1.12)p = 0.097.在竞争性风险分析中,经AHRF病史调整后,AHRF的比值比在12以内 月为0.30(95%CI 0.11-0.87)p = 0.024.LT-NIV组的病情恶化较少(中位数1(0-1)vs 2(1-4)p = 0.021)和AHRF再次入院(中位数0(0-1)vs 1(0-1)p = 0.016)。结论:主要转归的风险、AHRF再次入院的时间或12年内死亡 LT-NIV组的月数较小,但没有达到显著性。然而,一些次要结果分析,如AHRF的风险、AHRF发作次数和恶化都显著降低,有利于高压LT-NIV,尤其是在频繁AHRF的患者中。
{"title":"Long-term non-invasive ventilation for COPD patients following an exacerbation with acute hypercapnic respiratory failure: a randomized controlled trial.","authors":"Caroline Hedsund,&nbsp;Kasper Linde Ankjærgaard,&nbsp;Tine Peick Sonne,&nbsp;Philip Tønnesen,&nbsp;Ejvind Frausing Hansen,&nbsp;Helle Frost Andreassen,&nbsp;Ronan M G Berg,&nbsp;Jens-Ulrik Stæhr Jensen,&nbsp;Jon Torgny Wilcke","doi":"10.1080/20018525.2023.2257993","DOIUrl":"https://doi.org/10.1080/20018525.2023.2257993","url":null,"abstract":"<p><strong>Introduction: </strong>It remains unclear whether long-term non-invasive ventilation (LT-NIV) for patients with chronic obstructive pulmonary disease (COPD) improves survival and reduces admissions as results from randomized trials are inconsistent. We aim to determine whether LT-NIV initiated after an admission with acute hypercapnic respiratory failure (AHRF) can affect survival and admission rate in COPD patients.</p><p><strong>Methods: </strong>A randomized controlled open-label trial, allocating patients with COPD to LT-NIV or standard of care immediately after an admission with AHRF treated with acute NIV. LT-NIV was aimed to normalize PaCO<sub>2</sub> using high-pressure NIV.</p><p><strong>Results: </strong>The study was discontinued before full sample size due to slow recruitment. 28 patients were randomized to LT-NIV and 27 patients to standard of care. 42% of patients had a history of ≥ 2 admissions with AHRF. Median IPAP was 24 cmH<sub>2</sub>O (IQR 20-28). The primary outcome, time to readmission with AHRF or death within 12 months, did not reach significance, hazard ratio 0.53 (95% CI 0.25-1.12) <i>p</i> = 0.097. In a competing risk analysis, adjusted for history of AHRF, the odds ratio for AHRF within 12 months was 0.30 (95% CI 0.11-0.87) <i>p</i> = 0.024. The LT-NIV group had less exacerbations (median 1 (0-1) vs 2 (1-4) <i>p</i> = 0.021) and readmissions with AHRF (median 0 (0-1) vs 1 (0-1) <i>p</i> = 0.016).</p><p><strong>Conclusion: </strong>The risk of the primary outcome, time to readmission with AHRF or death within 12 months was numerically smaller in the LT-NIV group, however, did not reach significance. Nevertheless, several secondary outcome analyses like risk of AHRF, number of episodes of AHRF and exacerbations were all significantly reduced in favour of high-pressure LT-NIV, especially in patients with frequent AHRF.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/02/ZECR_10_2257993.PMC10512815.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41113805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19. 降钙素原不能用于诊断重症 COVID-19 患者的细菌性肺炎。
IF 1.9 Q3 Medicine Pub Date : 2023-02-08 eCollection Date: 2023-01-01 DOI: 10.1080/20018525.2023.2174640
Avi J Cohen, Laura R Glick, Seohyuk Lee, Yukiko Kunitomo, Derek A Tsang, Sarah Pitafi, Patricia Valda Toro, Nicholas R Ristic, Ethan Zhang, George B Carey, Rupak Datta, Charles S Dela Cruz, Samir Gautam

Background: Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection.

Methods: We retrospectively identified 185 patients hospitalized with severe COVID-19 who underwent lower respiratory culture; 85 had evidence of bacterial superinfection. Receiver operating characteristic curve and area under the curve (AUC) analyses were performed to assess the utility of procalcitonin for diagnosing superinfection.

Results: This approach demonstrated that procalcitonin measured at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). The AUC not affected by exposure to antibiotics, treatment with immunomodulatory agents, or timing of procalcitonin measurement.

Conclusion: Static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19.

背景:患有 COVID-19 的住院患者极有可能并发细菌性肺炎。然而,由于其临床表现与重症 COVID-19 相似,诊断叠加感染具有挑战性。因此,我们评估了免疫生物标志物降钙素原是否有助于诊断细菌性超级感染:我们回顾性地鉴定了 185 例因重症 COVID-19 住院并接受下呼吸道培养的患者,其中 85 例有细菌超级感染的证据。我们对接收者操作特征曲线和曲线下面积(AUC)进行了分析,以评估降钙素原对诊断超级感染的效用:结果:该方法表明,在培养时测量的降钙素原无法区分细菌感染患者(AUC,0.52)。AUC不受抗生素暴露、免疫调节剂治疗或降钙素原测量时间的影响:结论:静态测量降钙素原不能帮助诊断严重 COVID-19 的超级感染。
{"title":"Nonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19.","authors":"Avi J Cohen, Laura R Glick, Seohyuk Lee, Yukiko Kunitomo, Derek A Tsang, Sarah Pitafi, Patricia Valda Toro, Nicholas R Ristic, Ethan Zhang, George B Carey, Rupak Datta, Charles S Dela Cruz, Samir Gautam","doi":"10.1080/20018525.2023.2174640","DOIUrl":"10.1080/20018525.2023.2174640","url":null,"abstract":"<p><strong>Background: </strong>Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection.</p><p><strong>Methods: </strong>We retrospectively identified 185 patients hospitalized with severe COVID-19 who underwent lower respiratory culture; 85 had evidence of bacterial superinfection. Receiver operating characteristic curve and area under the curve (AUC) analyses were performed to assess the utility of procalcitonin for diagnosing superinfection.</p><p><strong>Results: </strong>This approach demonstrated that procalcitonin measured at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). The AUC not affected by exposure to antibiotics, treatment with immunomodulatory agents, or timing of procalcitonin measurement.</p><p><strong>Conclusion: </strong>Static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/b5/ZECR_10_2174640.PMC9930745.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9504032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation between parents and child's version of the child health survey for asthma questionnaire. 父母与孩子版儿童哮喘健康调查问卷的相关性。
IF 1.9 Q3 Medicine Pub Date : 2023-01-01 DOI: 10.1080/20018525.2023.2194165
Valbona Zhjeqi, Michael Kundi, Mimoza Shahini, Halil Ahmetaj, Luljeta Ahmetaj, Shaip Krasniqi

Background: The American Academy of Pediatrics Children's Health Survey for Asthma (CHSA) is a widely used instrument to assess various aspects of health and well-being in relation to asthma. There is a parent and a child version of this questionnaire and little is known about the concordance between these versions.

Method: In a cross-sectional study conducted in 13 facilities, hospitals and outpatient clinics covering all areas of Kosovo, children with asthma aged 7-16 years were enrolled. Information about asthma diagnosis was obtained from the treating physician. Children and parents answered the CHSA, parent or child version (CHSA-C) as well as a number of questions about environmental conditions, health insurance and socio-demographic characteristics.

Results: The survey included 161 Kosovar children with asthma and their caregivers. Although there were significant differences between parents and child versions regarding physical health, child activity and emotional health, with parents rating physical and emotional health higher and child activity lower, there were significant correlations (R > 0.7) for physical and child activity scales but only a low one (R = 0.25) for emotional health. Inspection of concordance for single items revealed very high correlations (>0.9) for all disease events, but a significant underestimation of the number of wheezing episodes by parents. Good agreement was found for statements about disease severity.

Conclusions: The high correlation between information about children's health obtained from parents and children underlines the usefulness of parents as source of information on child's asthma. Impact of the disease on emotional health is, however, underestimated by parents.

背景:美国儿科学会儿童哮喘健康调查(CHSA)是一种广泛使用的工具,用于评估与哮喘有关的健康和福祉的各个方面。这个问卷有父母和孩子版本,很少有人知道这些版本之间的一致性。方法:在覆盖科索沃所有地区的13个设施、医院和门诊诊所进行的一项横断面研究中,招募了7-16岁的哮喘儿童。哮喘诊断信息从治疗医师处获得。儿童和家长回答了CHSA,父母或儿童版本(CHSA- c)以及一些关于环境条件、健康保险和社会人口特征的问题。结果:调查对象为161名科索沃哮喘患儿及其照顾者。虽然父母和孩子的版本在身体健康、儿童活动和情绪健康方面存在显著差异,但父母对身体和情绪健康的评价较高,对儿童活动的评价较低,但在身体和儿童活动量表上存在显著相关性(R > 0.7),而在情绪健康量表上只有低相关性(R = 0.25)。对单个项目的一致性检查显示,所有疾病事件的相关性非常高(>0.9),但家长对喘息发作次数的估计明显偏低。关于疾病严重程度的陈述有很好的一致性。结论:从父母和儿童获得的儿童健康信息之间的高度相关性强调了父母作为儿童哮喘信息来源的有用性。然而,这种疾病对情绪健康的影响被父母低估了。
{"title":"Correlation between parents and child's version of the child health survey for asthma questionnaire.","authors":"Valbona Zhjeqi,&nbsp;Michael Kundi,&nbsp;Mimoza Shahini,&nbsp;Halil Ahmetaj,&nbsp;Luljeta Ahmetaj,&nbsp;Shaip Krasniqi","doi":"10.1080/20018525.2023.2194165","DOIUrl":"https://doi.org/10.1080/20018525.2023.2194165","url":null,"abstract":"<p><strong>Background: </strong>The American Academy of Pediatrics Children's Health Survey for Asthma (CHSA) is a widely used instrument to assess various aspects of health and well-being in relation to asthma. There is a parent and a child version of this questionnaire and little is known about the concordance between these versions.</p><p><strong>Method: </strong>In a cross-sectional study conducted in 13 facilities, hospitals and outpatient clinics covering all areas of Kosovo, children with asthma aged 7-16 years were enrolled. Information about asthma diagnosis was obtained from the treating physician. Children and parents answered the CHSA, parent or child version (CHSA-C) as well as a number of questions about environmental conditions, health insurance and socio-demographic characteristics.</p><p><strong>Results: </strong>The survey included 161 Kosovar children with asthma and their caregivers. Although there were significant differences between parents and child versions regarding physical health, child activity and emotional health, with parents rating physical and emotional health higher and child activity lower, there were significant correlations (<i>R</i> > 0.7) for physical and child activity scales but only a low one (<i>R</i> = 0.25) for emotional health. Inspection of concordance for single items revealed very high correlations (>0.9) for all disease events, but a significant underestimation of the number of wheezing episodes by parents. Good agreement was found for statements about disease severity.</p><p><strong>Conclusions: </strong>The high correlation between information about children's health obtained from parents and children underlines the usefulness of parents as source of information on child's asthma. Impact of the disease on emotional health is, however, underestimated by parents.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/61/ZECR_10_2194165.PMC10054174.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9241065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Clinical Respiratory Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1